

Datasheet for ABIN2666964  
**CXCL3 Protein (AA 28-100)**



[Go to Product page](#)

## Overview

Quantity:	10 µg
Target:	CXCL3
Protein Characteristics:	AA 28-100
Origin:	Mouse
Source:	Escherichia coli (E. coli)
Protein Type:	Recombinant
Biological Activity:	Active
Application:	Flow Cytometry (FACS)

## Product Details

Purity:	> 98 % , as determined by Coomassie stained SDS-PAGE.
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 0.01 ng per µg cytokine as determined by the LAL method.

## Target Details

Target:	CXCL3
Alternative Name:	CXCL3 ( <a href="#">CXCL3 Products</a> )
Background:	CXCL3 is an ELR CXC chemokine, and it is structurally and functionally related to GRO1 (CXCL1), GRO2 (CXCL2), and interleukin-8 (CXCL8). CXCL3 binds to the CXCR2 receptor, and this receptor is shared with other ELR CXC chemokines (CXCL1, CXCL2, CXCL5, CXCL6, CXCL7, and CXCL8). CXC chemokines play a crucial role in the first phase of inflammation, in this stage,

## Target Details

PMN cells are rapidly chemoattracted. In the next step of inflammation, the CC chemokines (MCPs) attract different cell subpopulations such as T cells, monocytes, basophils, and eosinophils. MMP12, mainly produced by macrophages, modulates the activity of ELR-CXC chemokines, and it cleaves human CXCL1, CXCL2 and CXCL3 within the ELR sequence at Glu6-Leu7. The ELR sequence is critical in receptor binding, therefore, the cleavage inactivates these chemokines and abrogates the PMN influx. CXCL3 is expressed in colon carcinoma, and it is associated with metastasis. Also, CXCL1, CXCL2 and CXCL3 have been shown to be highly expressed in patients with malignant melanoma. CXCL3, in addition to other chemokines, is induced by IL-17A in psoriasis. Also, CXCL3 and other pro-angiogenic ELR+ chemokines are induced by microparticles in synovial fibroblasts from patients with rheumatoid arthritis.

**Molecular Weight:** The 73 amino acid recombinant protein has a predicted molecular mass of approximately 7.9 kDa. The DTT-reduced and non-reduced protein migrate at approximately 10 and 12 kDa by SDS-PAGE respectively. The N-terminal amino acid is Ala.

**Pathways:** [Cellular Response to Molecule of Bacterial Origin, Autophagy](#)

## Application Details

**Application Notes:** Optimal working dilution should be determined by the investigator.

**Comment:** Biological activity: Bioactivity was measured by its property to chemoattract human neutrophils in a dose dependent manner.

**Restrictions:** For Research Use only

## Handling

**Format:** Liquid

**Reconstitution:** For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 µg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

**Buffer:** 0.22 µm filtered protein solution is in PBS.

**Handling Advice:** Avoid repeated freeze/thaw cycles.

**Storage:** -20 °C

**Storage Comment:** Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.